Abstract
Improving representation and inclusion in clinical trials for new medicinal products has been a high priority for federal agencies for over 2 decades, but data to evaluate progress have been difficult to access. In this issue of Patterns, Carmeli et al. provide a novel approach to aggregating and visualizing existing data to improve transparency and research.